Hong Kong Department of Health accepts IASO Bio’s NDA for equecabtagene autoleucel to treat r/r multiple myeloma: Shanghai, Nanjing Monday, February 17, 2025, 17:00 Hrs [IST] IA ...

The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...

Antengene’s Xpovio approved for reimbursement in Taiwan to treat adult patients with relapsed/refractory multiple myeloma: Shanghai Friday, February 14, 2025, 16:00 Hrs [IST] An ...

IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced ...

This review summarizes the mechanisms of action and clinical activity of IMiDs in MM. Multiple myeloma (MM) is a malignant plasma cell disorder accounting for approximately 10% of all hematologic ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

"The developers expect to create Russia's first drug for multiple myeloma based on CAR-NK therapy ... as it allows activating the natural mechanisms of the immune response and destruction of tumor ...

Although the treatment of myeloma has changed dramatically after the readout of many recent trials, key unanswered questions ...

Chimeric antigen receptor T-cell therapy has been really instrumental in how we treat patients with myeloma. It has really changed the face of how we treat this disease, so since 2021, we've had two ...

Medically reviewed by Marla Anderson, MD Multiple myeloma is a type of blood cancer that forms in plasma cells, white blood ...

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...

Daratumumab plus VRd significantly improves survival in newly diagnosed multiple myeloma, supporting its role as a new ...